Krystal Biotech's second quarter revenue of $119.2M missed estimates, while EPS of $1.79 beat.

Krystal Biotech reported mixed second quarter 2026 results, with its key product VYJUVEK missing revenue expectations while earnings per share came in ahead of forecasts. Global VYJUVEK net product revenue grew 24% year-over-year to $119.2 million, supported by durable demand in the U.S. and growing international sales.

Key Highlights

• Second quarter global VYJUVEK revenue was $119.2 million, a 24% increase year-over-year, but slightly below the consensus estimate of $122.61 million.
• Diluted EPS of $1.79 beat the analyst forecast of $1.70 and increased from $1.29 in the same quarter last year.
• The company maintains a strong balance sheet, ending the quarter with $1.1 billion in cash, cash equivalents, and investments.
• Management noted growing momentum in its initial international launch markets of Germany, France, and Japan, and is on track for VYJUVEK launches in Spain and Italy by year-end.